Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2026Anti-Cancer Agents in Medicinal Chemistry

Lazertinib: A Selective EGFR Mutant Inhibitor to Treat Non-Small Cell Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

HMHyma MandapakaSDSurya K. De

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates lazertinib's effectiveness in treating non-small cell lung cancer, suggesting promising outcomes.

Key Points

  • The aim is to evaluate the effectiveness of lazertinib as a selective treatment for EGFR-mutant non-small cell lung cancer.
  • Conducted a detailed investigation of lazertinib's pharmacological properties and clinical trial evidence.
  • Compared lazertinib with other agents like osimertinib regarding resistance mechanisms and treatment protocols.
  • Analyzed its role in first-line therapy and combination therapies for better outcomes.
  • Early-phase results show promising benefits of lazertinib against EGFR mutations.
  • Lazertinib demonstrates potential in overcoming the T790M resistance mutation.
  • Queries on resistance mechanisms and optimal treatment protocols continue, highlighting clinical uncertainties.

Cite This Study

Mandapaka et al. (2026) studied this question.

synapsesocial.com/papers/6a65a76fd3aea3239cd784bbhttps://doi.org/10.2174/0118715206446336251226053220
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lazertinib: A Cardio‐Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double‐Mutant Tyrosine Kinase Resistant Non‐Small Cell Lung Cancer2025 · 3 citations
  2. 2SUCCESSFUL TREATMENT OF METASTATIC LUNG ADENOCARCINOMA WITH LAZERTINIB: A CASE REPORT2024
  3. 3Real‐world study of lazertinib as second‐line or greater treatment in advanced non‐small cell lung cancer2024 · 1 citations
  4. 4Lazertinib versus Platinum-Based Chemotherapy with Epidermal Growth Factor Receptor (EGFR)-Positive Non-Small-Cell Lung Cancer after Failing EGFR-Tyrosine Kinase Inhibitor: A Real-World External Comparator Study2024 · 2 citations
  5. 5Central Nervous System Activity of Lazertinib in EGFR ‐Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG‐LU20‐15 and LU21‐012026